PSMA PET Imaging for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Is PSMA PET Imaging for Prostate Cancer safe for humans?
Studies on 68Ga-PSMA-11, a tracer used in PSMA PET imaging, have been conducted to assess its safety, showing that it is generally safe for human use. These studies have focused on understanding how the tracer spreads in the body and the radiation dose patients receive, which are important for ensuring safety.12345
How does PSMA PET Imaging for Prostate Cancer differ from other treatments?
PSMA PET Imaging for Prostate Cancer uses a novel tracer called 68Ga-PSMA, which is highly effective in detecting prostate cancer recurrence and metastases. This imaging technique is more sensitive and accurate than traditional CT scans, particularly in identifying nodal and skeletal metastases, making it a valuable tool for precise cancer localization.678910
What data supports the effectiveness of the treatment 68Ga-HBED-CC-PSMA for prostate cancer?
Research shows that 68Ga-HBED-CC-PSMA is effective in detecting prostate cancer and its recurrence, with higher accuracy than traditional CT scans. It has a high detection rate for localizing cancer sites, especially in patients with biochemical recurrence, and is more effective than other imaging methods like (18)F-Fluoroethylcholine PET/CT.7891011
Who Is on the Research Team?
Heiko Schöder, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for men over 18 with biopsy-proven prostate adenocarcinoma, whose PSA levels have risen by at least 2 ng/ml after initial treatments like surgery or radiation. They must be able to undergo PET/CT scans and not have claustrophobia or other issues that would make such imaging difficult.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo PET scan with Ga-HBED-iPSMA, possibly combined with CT or MRI
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- 68Ga-HBED-CC-PSMA
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor